When the risk of severe, potentially deadly skin reactions is found in association with one of the most widely used over-the-counter medications, you would think that warning the public would be a priority. But a year and a half after publishing an initial consumer update on the risk, the FDA is only now asking that a warning be placed on all acetaminophen-containing medications, including over-the-counter drugs.

Nine months of negotiations, an agreed-upon set of purchase terms and clinical trials already in progress according to FDA requirements—if a drug manufacturer has completed all of these in anticipation of purchasing the rights to a drug, is that proof enough that it was prepared and intended to enter the pharmaceutical market with it?

Jodi Westbrook Flowers

GM’s ignition switch defect has now been linked to 38 deaths. The ignition switch problem was so obvious that customers, journalists and even GM employees were reporting the problem a decade before GM finally admitted the issue and recalled the cars.

I am still amazed that I am writing this post and we are here today. However, I am gratified that the Supreme Court did not fall into BP’s game and indulge it by hearing its appeal of the Business and Economic Damages Settlement Agreement.